Shortly after its founding in 2005, Critical Path Institute began forging relationships with European entities. In 2007, C-Path’s Predictive Safety Testing Consortium (PSTC), which counted among its members European pharmaceutical company Novartis AG, was the first collaboration to use the Voluntary Exploratory Data Submission review process, which allowed them to submit qualification plans for seven kidney safety biomarkers to FDA and EMA simultaneously. In 2011, C-Path signed a Memorandum of Understanding (MoU) with the European Union’s Innovative Medicines Initiative (IMI) to further the missions of both organizations. Marking C-Path’s 10th anniversary in 2015, founder and former CEO Raymond Woosley, MD, PhD, reflected, “C-Path, because of its founding principles of trust, collaboration, and outstanding science, has become an internationally respected leader in advancing the innovative methods that are fundamentally changing the way new medicines are being developed.”